IDH2 and astrocytoma (excluding glioblastoma): Activating point mutations in platelet-derived growth factor receptor alpha (PDGFRA) were present in 6/17 (35.3%) of PMMRDIA, much more often than in supratentorial, high-grade IDH-mutant astrocytomas (9.1%).